Clinical Trial Update: Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma [Phase 3]

View source ↗

Summary

Phase 3 trial update on pomalidomide, bortezomib, and low-dose dexamethasone in relapsed or refractory multiple myeloma; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• Dexamethasone (low-dose) (dexamethasone)
• Pomalidomide (Pomalidomide)

Snippet

Sponsor: Celgene | Conditions: Multiple Myeloma | Phase 3 | Status: COMPLETED | Results posted: 2023-06-06